Clinical Utility of Monoclonal Gammopathy Testing in the Evaluation of Anemia

Descriptive graph of all patients tested in this cohort who were found to have new MG diagnoses through testing (11.8%), and the percentage of patients with a clinically significant monoclonal protein test (0.4%). Clinically significant tests were those that led to a new lymphoplasmacytic diagnosis or uncovered MG as the source of the patient's anemia for which they received monoclonal protein testing.